Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

Invivyd (IVVD)

Invivyd Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IVVD
DateTimeSourceHeadlineSymbolCompany
27/12/202421:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
02/12/202420:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
14/11/202414:16Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:IVVDInvivyd Inc
14/11/202412:24Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IVVDInvivyd Inc
14/11/202412:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
14/11/202412:05GlobeNewswire Inc.Invivyd Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:IVVDInvivyd Inc
14/11/202412:01GlobeNewswire Inc.Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the EditorNASDAQ:IVVDInvivyd Inc
12/11/202413:30GlobeNewswire Inc.Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRNASDAQ:IVVDInvivyd Inc
06/11/202413:01GlobeNewswire Inc.Invivyd to Participate in the Guggenheim Securities Healthcare Innovation ConferenceNASDAQ:IVVDInvivyd Inc
06/11/202412:01GlobeNewswire Inc.Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024NASDAQ:IVVDInvivyd Inc
29/10/202411:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
29/10/202411:03GlobeNewswire Inc.Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term ProfitabilityNASDAQ:IVVDInvivyd Inc
29/10/202411:01GlobeNewswire Inc.Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent ParticipantsNASDAQ:IVVDInvivyd Inc
16/10/202411:01GlobeNewswire Inc.Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024NASDAQ:IVVDInvivyd Inc
01/10/202411:01GlobeNewswire Inc.Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity DataNASDAQ:IVVDInvivyd Inc
23/09/202411:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
23/09/202411:01GlobeNewswire Inc.Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)NASDAQ:IVVDInvivyd Inc
12/09/202411:01GlobeNewswire Inc.Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19NASDAQ:IVVDInvivyd Inc
06/09/202413:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
05/09/202411:01GlobeNewswire Inc.Invivyd to Participate in Upcoming Investor ConferencesNASDAQ:IVVDInvivyd Inc
04/09/202411:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
04/09/202411:01GlobeNewswire Inc.Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™NASDAQ:IVVDInvivyd Inc
03/09/202411:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
03/09/202411:01GlobeNewswire Inc.Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of InterestNASDAQ:IVVDInvivyd Inc
27/08/202412:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
27/08/202411:01GlobeNewswire Inc.Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical TrialNASDAQ:IVVDInvivyd Inc
14/08/202412:25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IVVDInvivyd Inc
14/08/202412:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
14/08/202412:01GlobeNewswire Inc.Invivyd Reports Second Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:IVVDInvivyd Inc
12/08/202420:01GlobeNewswire Inc.Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business HighlightsNASDAQ:IVVDInvivyd Inc
 Showing the most relevant articles for your search:NASDAQ:IVVD

Your Recent History